Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research note issued on Monday, November 18th, TipRanks reports. They presently have a $72.50 target price on the stock. Chardan Capital’s price target would indicate a potential upside of 10.92% from the stock’s current price.
CRSP has been the subject of several other reports. William Blair reiterated a “hold” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $62.00 target price on shares of Crispr Therapeutics in a report on Wednesday, July 31st. Piper Jaffray Companies reiterated an “overweight” rating on shares of Crispr Therapeutics in a research note on Monday, October 21st. Canaccord Genuity began coverage on Crispr Therapeutics in a research report on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Finally, TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $69.54.
Crispr Therapeutics stock traded down $0.67 during midday trading on Monday, hitting $65.36. 739,581 shares of the stock were exchanged, compared to its average volume of 712,269. The company has a fifty day simple moving average of $58.93 and a two-hundred day simple moving average of $48.44. The stock has a market capitalization of $3.62 billion, a PE ratio of -19.00 and a beta of 3.31. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, equities research analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. Nikko Asset Management Americas Inc. increased its holdings in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares during the period. ARK Investment Management LLC raised its position in Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics during the third quarter worth $21,167,000. Price T Rowe Associates Inc. MD lifted its stake in Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares in the last quarter. 49.82% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is a Swap?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.